Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua

[1]  K. Koelle,et al.  Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases , 2020, Nature Communications.

[2]  A. Gordon,et al.  Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies , 2020, Proceedings of the National Academy of Sciences.

[3]  A. Monto,et al.  Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility , 2020, Nature Communications.

[4]  L. Brammer,et al.  The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century , 2019, PloS one.

[5]  F. Krammer.  The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.

[6]  E. Lau,et al.  Variation in Influenza B Virus Epidemiology by Lineage, China , 2018, Emerging infectious diseases.

[7]  M. L. Matute,et al.  Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014 , 2018, BMC Infectious Diseases.

[8]  J. Peiris,et al.  Age-specific differences in the dynamics of protective immunity to influenza , 2018, Nature Communications.

[9]  Sarah Cobey,et al.  Immune History and Influenza Vaccine Effectiveness , 2018, Vaccines.

[10]  A. Gordon,et al.  The Burden of Influenza: a Complex Problem , 2018, Current Epidemiology Reports.

[11]  T. Ross,et al.  Towards a universal influenza vaccine: different approaches for one goal , 2018, Virology Journal.

[12]  Catharine I Paules,et al.  The Pathway to a Universal Influenza Vaccine. , 2017, Immunity.

[13]  Edward A Belongia,et al.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence , 2017, Expert review of vaccines.

[14]  S. Hensley,et al.  Immune history and influenza virus susceptibility. , 2017, Current opinion in virology.

[15]  S. McColl,et al.  Vaccine‐Induced Antibody Responses Prevent the Induction of Interferon Type I Responses Upon a Homotypic Live Virus Challenge , 2016, Scandinavian journal of immunology.

[16]  Trevor Bedford,et al.  Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses , 2015, Proceedings of the National Academy of Sciences.

[17]  E. Harris,et al.  The Nicaraguan pediatric influenza cohort study: design, methods, use of technology, and compliance , 2015, BMC Infectious Diseases.

[18]  Trevor Bedford,et al.  Global circulation patterns of seasonal influenza viruses vary with antigenic drift , 2015, Nature.

[19]  A. von Haeseler,et al.  IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies , 2014, Molecular biology and evolution.

[20]  P. Horby,et al.  Determinants of Influenza Transmission in South East Asia: Insights from a Household Cohort Study in Vietnam , 2014, PLoS pathogens.

[21]  A. Cook,et al.  Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore , 2014, BMC Infectious Diseases.

[22]  J. Wong,et al.  Incidence of influenza virus infections in children in Hong Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[24]  W. B. Church,et al.  Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans , 2012, Immunology and cell biology.

[25]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[26]  T. Heikkinen,et al.  Seasonal influenza: the burden of disease in children. , 2011, Vaccine.

[27]  B. Johansson,et al.  Recombinant Influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines , 2008, Human vaccines.

[28]  S. Epstein.  Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. , 2006, The Journal of infectious diseases.

[29]  S. Itamura,et al.  Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. , 1991, The Journal of general virology.

[30]  A. Frank,et al.  Influenza B virus reinfection. , 1987, American journal of epidemiology.

[31]  R B Couch,et al.  Immunity to influenza in man. , 1983, Annual review of microbiology.

[32]  A. Frank,et al.  Variation in frequency of natural reinfection with influenza A viruses , 1983, Journal of medical virology.

[33]  A. Monto,et al.  Acute respiratory illness in an American community. The Tecumseh study. , 1974, JAMA.

[34]  H. S. Kaye,et al.  Studies on inactivated influenza vaccines. I. The effect of dosage on antibody response and protection against homotypic and heterotypic influenza virus challenge in mice. , 1969, American journal of epidemiology.